416. Deputy John Clendennen asked the Minister for Health whether the pharmacoeconomic and reimbursement assessment of belzutifan for von Hippel Lindau disease takes account of the full long-term healthcare costs associated with the natural progression of the disease and repeated treatment of VHL-associated tumors including renal surgery, loss of renal function, chronic kidney disease, dialysis, renal transplantation and other VHL-related interventions; and the manner in which such potentially avoided or deferred costs are incorporated into the assessment. [66248/26]

Summary

416. Deputy John Clendennen asked the Minister for Health whether the pharmacoeconomic and reimbursement assessment of belzutifan for von Hippel Lindau disease takes account of the full long-term healthcare costs associated with the natural progression of the disease and repeated treatment of VHL-associated tumors including renal surgery, loss of renal function, chronic kidney disease, dialysis, renal transplantation and other VHL-related interventions; and the manner in which such potentially avoided or deferred costs are incorporated into the assessment. [66248/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 17 September 2026

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.